Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Blomgren

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|May 1, 2014
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinaseKevin S Currie, Jeffrey E Kropf, Tony Lee, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune DiseasesPeter Blomgren, Jayaraman Chandrasekhar, Julie A Di Paolo, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Medicinal Chemistry|May 1, 2014
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinaseKevin S Currie, Jeffrey E Kropf, Tony Lee, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune DiseasesPeter Blomgren, Jayaraman Chandrasekhar, Julie A Di Paolo, et al.
ACS Medicinal Chemistry Letters|March 19, 2020
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)ValidationJulie Farand, Jeffrey E Kropf, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2015
Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stabilityWendy B Young, James Barbosa, Peter Blomgren, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2015
Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834Wendy B Young, James Barbosa, Peter Blomgren, et al.
JCI Insight|April 14, 2017
Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN<b>α</b>-driven lupus nephritisArna Katewa, Yugang Wang, Jason A Hackney, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Pageof 2